How to buy Olema Pharmaceuticals stock | $27.96

Olema Pharmaceuticals, Inc is a biotechnology business based in the US. Olema Pharmaceuticals shares (OLMA) are listed on the NASDAQ and all prices are listed in US Dollars. Olema Pharmaceuticals employs 36 staff and has a market cap (total outstanding shares value) of 0.00.

Olema Pharmaceuticals stock price (NASDAQ: OLMA)

Use our graph to track the performance of OLMA stocks over time.

Olema Pharmaceuticals shares at a glance

• Key figures

Information last updated 2021-07-28.

Latest market close	$27.96
52-week range	$19.41 - $60.27
50-day moving average	$26.71
200-day moving average	$33.93
Wall St. target price	$58.33
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy Olema Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Olema Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Olema Pharmaceuticals, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Olema Pharmaceuticals price performance over time

Historical closes compared with the close of $27.96 from 2021-05-28

1 week (2021-07-23)	N/A
1 month (2021-07-02)	4.84%
3 months (2021-05-03)	8.37%
6 months (2021-01-30)	N/A

1 year (2020-07-30)	N/A
2 years (2019-07-30)	N/A
3 years (2018-07-30)	N/A
5 years (2016-07-30)	N/A

Olema Pharmaceuticals financials

Gross profit TTM	$0
Return on assets TTM	-7.85%
Return on equity TTM	-13.13%
Profit margin	0%
Book value	$8.26
Market capitalisation	$948 million

TTM: trailing 12 months

Shorting Olema Pharmaceuticals shares

There are currently 2.4 million Olema Pharmaceuticals shares held short by investors – that's known as Olema Pharmaceuticals's "short interest". This figure is 7.7% up from 2.3 million last month.

There are a few different ways that this level of interest in shorting Olema Pharmaceuticals shares can be evaluated.

Olema Pharmaceuticals's "short interest ratio" (SIR)

Olema Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Olema Pharmaceuticals shares currently shorted divided by the average quantity of Olema Pharmaceuticals shares traded daily (recently around 277532.64840183). Olema Pharmaceuticals's SIR currently stands at 8.76. In other words for every 100,000 Olema Pharmaceuticals shares traded daily on the market, roughly 8760 shares are currently held short.

To gain some more context, you can compare Olema Pharmaceuticals's short interest ratio against those of similar companies.

• Puma Biotechnology (PBYI.US): 5.96
• Xenetic Biosciences (XBIO.US): 0.44
• Inovio Pharmaceuticals (INO.US): 10.45
• Oncorus (ONCR.US): 5.17

However Olema Pharmaceuticals's short interest can also be evaluated against the total number of Olema Pharmaceuticals shares, or, against the total number of tradable Olema Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Olema Pharmaceuticals's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Olema Pharmaceuticals shares in existence, roughly 60 shares are currently held short) or 0.1282% of the tradable shares (for every 100,000 tradable Olema Pharmaceuticals shares, roughly 128 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Olema Pharmaceuticals.

Find out more about how you can short Olema Pharmaceuticals stock.

Olema Pharmaceuticals share dividends

We're not expecting Olema Pharmaceuticals to pay a dividend over the next 12 months.

Olema Pharmaceuticals overview

Olema Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc.

Frequently asked questions

What percentage of Olema Pharmaceuticals is owned by insiders or institutions?
Currently 9.523% of Olema Pharmaceuticals shares are held by insiders and 88.879% by institutions. How many people work for Olema Pharmaceuticals?
Latest data suggests 36 work at Olema Pharmaceuticals. When does the fiscal year end for Olema Pharmaceuticals?
Olema Pharmaceuticals's fiscal year ends in December. Where is Olema Pharmaceuticals based?
Olema Pharmaceuticals's address is: 512 2nd Street, San Francisco, CA, United States, 94107